Dr. Weiner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3970 Reservoir Rd Nw
Lccc Georgetown University Medical Center Room E501
Washington, DC 20007Phone+1 202-687-2110Fax+1 202-687-6402
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
University of Vermont Medical CenterResidency, Internal Medicine, 1977 - 1981
Icahn School of Medicine at Mount SinaiClass of 1977
Certifications & Licensure
DC State Medical License 2008 - 2024
PA State Medical License 1984 - 2022
VT State Medical License 1978 - 1984- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Join now to see all
Publications & Presentations
PubMed
- 236 citationsInfluence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid TumorsStephen I. Rudnick, Jianlong Lou, Calvin Shaller, Yong Tang, Andres J. Klein-Szanto
Cancer Research. 2011-03-15 - 3 citationsThe Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.Alexander A Lekan, Louis M Weiner
Cancers. 2024-01-28 - 136 citationsSynergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2Eric F. Zhu, Shuning A. Gai, Cary F. Opel, Byron Hua Kwan, Rishi Surana
Cancer Cell. 2015-04-13
Press Mentions
Title: How Two Doctors Are Using Research to Push the Field of MedicineMay 25th, 2023- Key Studies Conducted at Georgetown Lombardi Lead to Better Treatment for People with MelanomaMarch 1st, 2023
- Reshaping Cancer Clinical Trials to Reflect Current Needs and ProgressDecember 22nd, 2022
- Join now to see all
Grant Support
- Determinants Of Tumor Sensitivity To Egfr-Targeted AntibodiesNational Cancer Institute2009–2012
- Tissue Culture Shared ResourceNational Cancer Institute2010–2011
- Senior LeadershipNational Cancer Institute2010–2011
- Protocol-Specific Research SupportNational Cancer Institute2010–2011
- Protocol Review And Monitoring SystemNational Cancer Institute2010–2011
- Proteomics And MetabolomicsNational Cancer Institute2010–2011
- Program LeadersNational Cancer Institute2010–2011
- Preclinical Imaging Research LaboratoryNational Cancer Institute2010–2011
- Planning And EvaluationNational Cancer Institute2010–2011
- Novel Targets In Endocrine ResponsivenessNational Cancer Institute2010–2011
- Microscopy And ImagingNational Cancer Institute2010–2011
- Histopathology And TissueNational Cancer Institute2010–2011
- Georgetown University, Lombardi Cancer Center Support Grant Competitive RenewalNational Cancer Institute2010–2011
- Genomics And EpigenomicsNational Cancer Institute2010–2011
- Flow Cytometry/Cell SortingNational Cancer Institute2010–2011
- Familial Cancer RegistryNational Cancer Institute2010–2011
- Developmental FundsNational Cancer Institute2010–2011
- Data And Safety Monitoring/Nih PolicyNational Cancer Institute2010–2011
- Clinical Research Management OfficeNational Cancer Institute2010–2011
- Clinical And Molecular EpidmiologyNational Cancer Institute2010–2011
- Biostatistics And BioinformaticsNational Cancer Institute2010–2011
- Animal Shared ResourceNational Cancer Institute2010–2011
- AdministrationNational Cancer Institute2010–2011
- Adaptive Immunity From High Affinity Anti-Her2/Neu Monoclonal AntibodiesNational Cancer Institute2008–2010
- Cancer Center Support GrantNational Cancer Institute2006–2009
- Monoclonal Antibody Therapy Induction Of Adaptive ImmunityNational Cancer Institute2008
- Monoclonal Antibody Therapy Induction Of Adaptive ImmunityNational Cancer Institute2007
- Adaptive Immunity From High Affinity Anti-Her2/Neu Monoclonal AntibodiesNational Cancer Institute2006–2007
- Antibody-Targeted NK Cell Activation For Cancer TherapyNational Cancer Institute2003–2007
- Guava Personal Cell Analysis-96 System: CancerNational Center For Research Resources2006
- Guava Easycyte Base System (Guava Personal Cell Analysis-96 System)National Center For Research Resources2006
- Gene Expression In Circulating Tumor CellsNational Cancer Institute2005–2006
- Conference On Antibody-Based Therapeutics For CancerNational Cancer Institute2004
- Gene Expression In Circulating Tumor CellsNational Cancer Institute2003
- Antibody-Based Therapeutics For CancerNational Cancer Institute2003
- Tumor And Endothelial Cells As Drug Targets In BloodNational Cancer Institute2002–2003
- Antibody-Targeted Immunotherapy Of CancerNational Cancer Institute1999–2002
- Tumor Targeting By Single Chain FV MoleculesNational Cancer Institute1997–2002
- Eastern Cooperative Oncology GroupNational Cancer Institute1996–2002
- Clinical Oncology Research Career Development ProgramNational Cancer Institute1992–2001
- Tumor Targeting By Single-Chain FV MoleculesNational Cancer Institute1996–1998
- Targeted Immunotherapy Using Bispecific AntibodiesNational Cancer Institute1996–1998
- Clinical Development Of 2B1 Bispecific Monoclonal ABNational Cancer Institute1993–1996
- Bispecific Anti-Tumor FC Gamma R III Monoclonal AntibodyNational Cancer Institute1993–1995
- Bispecific Anti-Tumor/Fcyr III Monoclonal AntibodiesNational Cancer Institute1989–1991
- NCI Clinical Investigator Award ProgramNational Cancer Institute1986–1988
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
